Dr. Andrea Small-Howard to Moderate Panel at "State of Cannabis" Conference on the Queen Mary

Dr. Andrea Small-Howard will be featured in the “Meeting of the Minds” at the two-day educational conference hosted on the historic Queen Mary.

LAS VEGAS, Sept. 18, 2018 /PRNewswire/ — GB Sciences, Inc. (OTCQB: GBLX) announces that Dr. Andrea Small-Howard will be moderating the panel discussion which kicks-off the “Cannabis Is Medicine Track” and explores important Research Initiatives. Of great interest to this panel is The Medical Cannabis Research Act of 2018, which was unanimously approved by the House Judiciary Committee with widespread bipartisan support on September 13th.

Click Here for Conference Details

This unprecedented legislation will expand the number of federal licenses granted for growing and studying cannabis by at least two new applicants; thus, ending the University of Mississippi’s fifty-year reign as the sole source of cannabis for research in the US. This bill also contains a provision that will allow the Department of Veterans Affairs to conduct research on medical cannabis, which has been an area of great interest for panelist, Dr. Sue Sisley, a leading clinical expert in the treatment of posttraumatic stress disorder (PTSD). The other esteemed panelists joining Dr. Small-Howard, include Dr. Daniele Piomelli, pioneering endocannabinoid system researcher and Director of the Institute for the Study of Cannabis at the University of California, Irvine, and Dr. Mowgli Holmes, CEO & Chief Scientific Officer at Phylos Bioscience in Oregon.

“Most Americans and our government seem to agree that there is an urgent need for more research on the medical applications of cannabis and the potential for any adverse effects as a result of using this Schedule I compound, yet performing US FDA-registered clinical trials while following the current federal rules is still incredibly difficult with barriers that do not exist in other kinds of research,” said Dr. Small-Howard. “The Medical Cannabis Research Act of 2018 addresses some of these challenges by expanding the number of federal cannabis suppliers, which should also increase the variety of cannabis strains cultivated and improve the quality and standardization of these cannabis research materials.”

John Poss, Chairman of the Board and CEO of GB Sciences, states: “We are proud to be represented by Andrea in such a prestigious think tank.  GB believes that in the world of cannabis: patients always come first.”

About GB Sciences, Inc.

GB Sciences, Inc. (OTCQB: GBLX) is a diverse cannabis company, focused on standardized cultivation and production methods; as well as biopharmaceutical research and development. The Company’s goal is creating safe, standardized, pharmaceutical-grade, cannabinoid therapies that target a variety of medical conditions. To learn more about GB Sciences, Inc., go to: http://gbsciences.com.

Forward-Looking Statements

This press release may contain statements relating to future results or events, which are forward-looking statements.  Words such as “expects”, “intends”, “plans”, “may”, “could”, “should”, “anticipates”, “likely”, “believes” and words of similar import may identify forward-looking statements. These statements are not historical facts, but instead represent only the Company’s belief regarding future events, many of which, by their nature, are inherently uncertain and outside of the Company’s control.  It is possible that the Company’s actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements.  Further, information concerning the Company and its business, including factors that potentially could materially affect the Company’s business and financial and other results, are contained in the Company’s filings with the Securities and Exchange Commission, available at www.sec.gov.  All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.

Note:  Although the Company’s research and development activities are not illegal, the production and sale of cannabis products violate federal laws as they presently exist.

Contact Information


GB Sciences, Inc., 3550 West Teco Ave., Las Vegas, NV 89118

866-721-0297, or

Tom Arcuragi, EVP, tom@gbsciences.com